Korea's drug register changes every month, and most of the change never reaches a product page. This report reads the register for the injectable ingredients behind the KSTATION range for September and October 2026. Three filings were granted: a polydeoxyribonucleotide (PDRN) injection, a 100 unit botulinum toxin and an export-only vitamin C. Four left, and they left in two different ways.
New Korean injectable licences, September and October 2026
| Granted | Filing | Ingredient | Licence holder | Contract manufacturer |
|---|---|---|---|---|
| 8 Sep 2026 | 다나은주 (Danaeun Inj.) | PDRN | KS Pharm. Inc. | ㈜비알팜 |
| 21 Sep 2026 | 톡스타주100단위 (TOXTA Inj. 100U) | Botulinum toxin type A | Firson Co., Ltd. | (주)제테마 |
| 6 Oct 2026 | 하이플비타민씨주(수출용) (Highfly Vitamin C Inj., for export) | Ascorbic acid | Highfly Life Science Co., Ltd. | (주)비씨월드제약 |
Danaeun Inj. is a PDRN injection packed as ten 3 mL vials per box, described in the register as a colourless, clear liquid in a clear vial. It is the only new PDRN filing in the two months, and it arrived two days after an older PDRN filing expired (below).
TOXTA Inj. 100U is a vacuum-dried powder in a single 100 unit vial. Its place in the TOXTA line and in the wider sequence of Korean toxin approvals is covered in our TOXTA profile and in the four waves of Korean toxin licences, so it is listed here for completeness only.
What "for export" means on a Korean licence
The vitamin C filing carries the suffix 수출용, recorded in English as "for export", in its product name. That suffix is how the register marks a licence granted for products made in Korea for sale abroad. It is part of the name on file, so an export filing and a domestic filing for the same ingredient are separate entries, even from the same company.
The Highfly filing is ten 20 mL brown vials per box, a pale yellow, clear solution, made under contract by BC World Pharm for the licence holder.
Korean injectable filings that left the register
| Date | Filing | Ingredient | Licence holder | Granted | Status |
|---|---|---|---|---|---|
| 6 Sep 2026 | 폴리뉴클레오주 (SUNGYI POLYDEOXYRIBONUCLEOTIDE SODIUM) | PDRN | SUNGYI BIO CO., LTD. | 6 Sep 2021 | Validity period expired |
| 12 Sep 2026 | 비씨업주 (Vi-C UP Inj.) | Ascorbic acid | Dongkwang Pharm. Co., Ltd. | 12 Sep 2016 | Validity period expired |
| 28 Oct 2026 | 하이록소주 (Hyroxo Injection) | Hydroxocobalamin | IL-YANG BIOPHARM. CO., LTD. | 24 Nov 2006 | Withdrawn |
| 28 Oct 2026 | 티옥센주 (Thiocsen Inj.) | Thioctic acid | YUNGJIN PHARM. CO., LTD | 9 Jul 2019 | Withdrawn |
Expired and withdrawn are two different endings
The register does not record these four the same way, and the difference matters when reading any count of licences that "left". Two of them carry the status 유효기간만료, validity period expired. Two carry 취하, withdrawn.
The two expired filings both ended on the exact anniversary of their grant date. The SUNGYI PDRN filing was granted on 6 September 2021 and expired on 6 September 2026, five years on. Vi-C UP was granted on 12 September 2016 and expired on 12 September 2026, ten years on. Neither was withdrawn; each reached the end of its validity period on the register.
The two withdrawals happened on the same day, 28 October 2026, from two unrelated companies. Hyroxo had been on the register for almost twenty years, since November 2006, and Thiocsen for a little over seven. The register records that each was withdrawn and when. It does not record why, and a same-day pair is not evidence of a common reason.
Six of the seven name a contract manufacturer
Of the seven filings in the two tables, six name a contract manufacturer in the register, a company other than the licence holder that makes the product. TOXTA Inj. 100U is made by Jetema for Firson; Danaeun by BR Pharm for KS Pharm; the Highfly vitamin C by BC World Pharm; the SUNGYI PDRN by Humedix; Hyroxo by Huons; Thiocsen by Aju Pharm. Vi-C UP is the only one with the field empty. For these filings, the name on the licence and the name of the factory are usually different, which is why a carton can carry two company names and still be consistent with the register.
Sodium hyaluronate moved three times, and none were fillers
Three sodium hyaluronate drug filings also changed in these two months, and none of them belongs in an aesthetic report. A new filing in October, HyalCare Inj. from Hanlim Pharm, is recorded for use in eye surgery. A new filing in September, Hyalo Plus Inj. from NexPharm Korea, is a gel cross-linked with 1,4-butanediol diglycidyl ether (BDDE) and recorded for the knee joint. A withdrawal in October, Hynalubon Inj. from Ildong Pharmaceutical, granted in 2013, was a joint product as well.
Hyalo Plus is worth a second look because BDDE is also the cross-linker named on many HA dermal filler pages. A cross-linked HA gel filed in the drug register is not a filler: Korean HA dermal fillers are filed as medical devices, in a separate register. A count of sodium hyaluronate drug licences is therefore a count of eye, joint and other products, not of fillers.
Ingredients with no change in either month
No injectable filing for glutathione, placenta extract, L-carnitine, tranexamic acid, lidocaine or prilocaine was granted, withdrawn or expired between 1 September and 31 October 2026.
Where the KSTATION range meets these filings
One company in these tables also appears in our range under its own licence. Huons, the contract manufacturer recorded for the withdrawn Hyroxo, holds the filing for HYCOMIN, a hydroxocobalamin injection granted in February 2002 and live on 5 November 2026. The withdrawal of Hyroxo does not touch that filing. Our vitamin and other injectables, including BC ASCORBIC, sit under vitamins and injectables. When a licence in a carton's small print changes status, the status word is the part to read.
Frequently asked
What new Korean injectable licences were granted in October 2026?
For the aesthetic ingredients this report follows, one: Highfly Vitamin C Inj. (for export), an ascorbic acid injection from Highfly Life Science, granted on 6 October 2026. September added Danaeun Inj. (PDRN) and TOXTA Inj. 100U.
What is the difference between a withdrawn and an expired Korean drug licence?
The register records them as different statuses. Expired (유효기간만료) means the licence's validity period ended; both expired filings here ended on the anniversary of their grant. Withdrawn (취하) means the filing was withdrawn; the register gives a date but no reason.
Are sodium hyaluronate drug licences in Korea dermal fillers?
No. The sodium hyaluronate filings that changed in September and October 2026 were for eye surgery and joints. Korean HA dermal fillers are filed as medical devices, not in the drug register.
Sources and references
- Ministry of Food and Drug Safety (MFDS), drug product licence register (open data service), list and detail records for injectable filings of 13 aesthetic ingredient groups, fields for grant date, status, status date, licence holder, contract manufacturer, description, pack units and recorded use, retrieved 5 November 2026.
- KSTATION editorial policy, on how register facts are separated from product claims in our writing.
Register entries are as retrieved on 5 November 2026 and can be corrected or updated after that date. This report records licence events for professional buyers. It says nothing about the clinical use or performance of any product.






